Skip to main navigation
Sana Biotechnology, Inc Logo

    Investor Relations

  • Home
  • News Releases
  • Events and Presentations
  • Corporate Governance
    Documents & Charters Our Team Committee Composition
  • Stock
    Stock Quote & Chart Historic Price Lookup
  • Financial Information
    SEC Filings
  • Resources
    Email Alerts Contact IR

News Releases

May 12, 2022
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D.
May 10, 2022
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates
Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file INDs this year for ex vivo hypoimmune allogeneic CAR T and in vivo fusogen CAR T SEATTLE, May 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc.
May 04, 2022
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference at 3:20 p.m.
May 02, 2022
Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts covering preclinical data from its hypoimmune and fusogen platforms were accepted for either oral or
Mar 16, 2022
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
Plans to present data at multiple scientific conferences in 2022 Expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022 2021 year-end cash position of $746.9 million SEATTLE, March 16, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc.
Mar 09, 2022
Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference
SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 32 nd Annual Oppenheimer Healthcare Conference at 6:20 a.m.
Mar 08, 2022
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data from its hypoimmune T cell program will be presented at the 2022 American Association for Cancer
Jan 11, 2022
Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
License will enable Sana’s in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell therapies SEATTLE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc.
Jan 10, 2022
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
Agreement combines IASO Bio and Innovent’s CAR construct, validated in clinical trials, with Sana’s in vivo and ex vivo engineered cell therapy programs SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan.
Jan 04, 2022
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 40 th Annual J.P. Morgan Healthcare Conference at 10:30 a.m.

Shareholder Tools

  • Print Page
  • Email Alerts
  • RSS
  • © 2020-2022 Sana Biotechnology, Inc. All rights reserved.

Footer Bottom

  • Privacy Policy |
  • Terms of Use